| Document |
Document Title |
|
WO/2021/068943A1 |
Disclosed in the present invention are a substituted nitrogen heterocyclic compound and anesthetic action thereof. Specifically provided are a chemical compound as shown in formula I, a stereoisomer thereof, a pharmaceutically acceptable...
|
|
WO/2021/062273A1 |
Described herein are methods for evaluating polymer compositions comprising polymers modified with a small molecule compound (e.g., afibrotic compound), including methods for determining the concentration levels of said compounds.
|
|
WO/2021/054459A1 |
A benzotriazole compound represented by formula (1). In formula (1), R1 to R4 represent substituents. In formula (1), n1 represents an integer from 0 to 4, and n2 represents an integer from 0 to 3.
|
|
WO/2021/049064A1 |
According to the present invention, a heterocyclic compound having a structure in which a benzene ring and a nitrogen-containing heterocycle are are fused through condensation is added to a sulfuric acid solution that contains, as an oxi...
|
|
WO/2021/049522A1 |
A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q1 represents a pyrazine ring or the like; G1 represents a nitrogen atom or a carbon atom; X1 represents an alkyl group or the like; m rep...
|
|
WO/2021/043966A1 |
The present invention relates to substituted5-membered nitrogen containing heteroaryl compounds, such as triazole esters, where the heteroaryl ring is further substituted via a linking group such as - NH- with a cyclic group which in tur...
|
|
WO/2021/042169A1 |
The present invention generally relates to nitrification inhibitors and compositions comprising nitrification inhibitors. The present invention also relates to use of the nitrification inhibitors and compositions for application to ferti...
|
|
WO/2021/031788A1 |
Disclosed are an immune checkpoint inhibitor capable of blocking a PD-1/PD-L1 signaling pathway, a phenyl-substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt, racemate, optical isomer or solvent compound...
|
|
WO/2020/247819A3 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2021/035196A1 |
Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need t...
|
|
WO/2021/029464A1 |
The present invention relates to a compound for an organic light emitting diode, an organic light emitting diode using same, and an electronic device comprising the organic light emitting diode. According to the present invention, it is ...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/023843A1 |
Processes for preparing (((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3
,4-c]pyrrol-2(1H)-yl)(2-fluoro-6-(2H-l,2,3-triazol-2- yl)phenyl)methanone are described, which are useful for commercial manufacturing. Said compound is...
|
|
WO/2021/022604A1 |
Disclosed is a pharmaceutical composition, a crystal form of prothioconazole, a preparation method, and an application thereof, belonging to the field of bactericide. The X-ray powder diffraction pattern of the crystal form of prothiocon...
|
|
WO/2021/021761A1 |
Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system...
|
|
WO/2021/022103A1 |
The disclosure generally relates to cocrystals of posaconazole and a coformer. The disclosure further relates to pharmaceutical compositions comprising the cocrystals, as well as methods of making the cocrystals, and methods of treating ...
|
|
WO/2021/012264A1 |
Provided is a triazole sulfonamide derivative as well as a preparation method therefor and an application thereof. Specifically provided are a triazole sulfonamide derivative represented by formula (I), or a stereoisomer, nitrogen oxide,...
|
|
WO/2021/016594A1 |
The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof wherein R1 is selected from the group of ...
|
|
WO/2021/013721A1 |
The invention relates to novel compounds of formula (I), where Ar represents phenyl or a 5- or 6-membered heteroaromatic ring and A, R1 and R2 are defined as aforementioned, and also relates to the use of said compounds for controlling a...
|
|
WO/2021/010337A1 |
The invention is the light-emitting compound represented by formula (1), or a salt thereof.
|
|
WO/2021/010340A1 |
The present invention is a luminescent compound represented by formula (1) or a salt thereof. (In formula (1), k represents 0 or 1; at least one of X and Y represents an optionally substituted heterocyclic group containing a nitrogen ato...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/010331A1 |
The present invention is a light-emitting compound represented by formula (1) or a salt thereof.
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2020/210174A4 |
The present disclosure provides methods for producing N-(fluorosulfonyl)azoles, sulfonyldiazoles, or related derivatives thereof; and the related products including N- (fluorosulfonyl)azoles, sulfonyldiazoles, and related derivatives the...
|
|
WO/2021/001825A1 |
The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides...
|
|
WO/2021/000755A1 |
Provided in the present invention is a small-molecule regulator of TLR8; a compound of formula (I) or the pharmaceutically acceptable salt thereof of the present invention have a good TLR8 regulation activity and can be used to prevent o...
|
|
WO/2020/253895A1 |
The present invention claims compounds of general formula I: (I) wherein the meaning of individual substituents is described in the claims. The compounds are useful in treatment of cancers, due to their multi-modal mechanism of action.
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/248065A1 |
The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemic...
|
|
WO/2020/249760A1 |
The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly h...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/246484A1 |
The purpose of the present invention is: to provide, as a material for a highly efficient and highly durable organic EL element, an organic compound that has excellent characteristics such as excellent electron injection and transport pe...
|
|
WO/2020/242948A1 |
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specif...
|
|
WO/2020/242277A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising: a naphthoquinone or benzoindazole compound which increases the ratio of NAD+ and NAD+/NADH through activi...
|
|
WO/2020/232807A1 |
Provided are a naphthoquinone fused triazole derivative, preparation method and application thereof. The naphthoquinone fused triazole derivative has a structure represented by the following formula (I), wherein X is C or N; R 1, R 2, R ...
|
|
WO/2020/229398A1 |
The invention relates to new compounds of the formula (I) wherein Ar represents phenyl or a 5- or 6-membered heteroaromatic ring and A, R1, R2, R3, and R4 are defined as above. The invention also relates to the use thereof for controllin...
|
|
WO/2020/230134A1 |
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral...
|
|
WO/2020/210174A3 |
The present disclosure provides methods for producing N-(fluorosulfonyl)azoles, sulfonyldiazoles, or related derivatives thereof; and the related products including N- (fluorosulfonyl)azoles, sulfonyldiazoles, and related derivatives the...
|
|
WO/2020/227368A1 |
Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.
|
|
WO/2020/227156A1 |
The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeu...
|
|
WO/2020/227097A1 |
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
|
|
WO/2020/223678A1 |
The present invention provides an improved process for preparation of the (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1
-yl)acrylic acid (referred to as compound of the structural formula (III)), which is a useful key inte...
|
|
WO/2019/171161A8 |
PCT00760 20 ABSTRACT Disclosed herein is a process for preparation of 1-chloro-2-(1- chlorocyclopropyl)-3-(2-chlorophenyl)propan-2-ol (compound of formula (I)) 5 and 2-(1-chlorocyclopropyl)-2-[(2-chlorophenyl)methyl]oxirane (compound of ...
|
|
WO/2020/216766A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...
|
|
WO/2020/216115A1 |
The present invention belongs to the technical field of petrochemical engineering, and relates to a method for continuous post-treatment of a benzotriazole (abbreviated as BTA) synthetic fluid. In particular, the present invention relate...
|
|
WO/2020/218609A1 |
Provided is an ultraviolet absorber which has particularly favorable heat resistance, suppression of odor during thermal decomposition, and long-wavelength absorption, and has a high molar extinction coefficient, compared with convention...
|
|
WO/2019/178305A8 |
The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1 ) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of -P(0)(OH)2, -P(0)(OH)(...
|
|
WO/2020/214545A1 |
Improved methods and intermediates thereof for preparing carbamoyloxy methyl triazole cyclohexyl acid compounds are described. These compounds are useful as LPA antagonists. Formula (I).
|
